Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients

作者
John P. Feighner,Lev Sverdlov,Joseph Hlavka,Gabriela Nicolau,Kenneth Cartwright,Jeffrey S. Freed
出处
期刊:International Clinical Psychopharmacology [Wolters Kluwer]
卷期号:23 (1): 29-35 被引量:7
标识
DOI:10.1097/yic.0b013e32817396c2
摘要

Clinical data were evaluated from an open-label, single-center, pilot study in patients with chronic refractory depression. The primary efficacy criterion was the change from baseline using the Montgomery-Asberg Depression Rating Scale. The secondary efficacy criteria were the 17-item Hamilton Depression Rating Scale and the Clinical Global Impression-Improvement scale. Response to treatment (40-240 mg once per day by subcutaneous injection for 10-20 doses) was defined as more than 50% improvement in the Montgomery-Asberg Depression Rating Scale from baseline or Clinical Global Impression-Improvement < or =2 and lasting for at least two sequential weeks. Patients with a sustained response at the end point in the acute main treatment phase were enrolled for up to 2 years in a maintenance phase of the study to determine duration of response and to initiate retreatments upon relapse. Of the 25 patients with chronic refractory depression, 11 patients showed a response for Montgomery-Asberg Depression Rating Scale and one responded according to the secondary criterion Hamilton Depression Rating Scale. In seven of the 11 responders to Montgomery-Asberg Depression Rating Scale the effects were sustained for the remainder of the acute phase. Two additional sustained responders identified according to secondary criteria (Hamilton Depression Rating Scale or Clinical Global Impression-Improvement) were also enrolled in the maintenance phase. All nine sustained responders were retreated, as needed, in the maintenance phase of the study, ranging from 71 to 660 days. Mean duration of response following initial treatment and between retreatments was around 2 months. Pharmacokinetic data indicated dose-proportional systemic exposure to the drug.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼的应助被kobe采纳,获得10
刚刚
性感锅包肉完成签到,获得积分10
刚刚
笨笨芝麻完成签到,获得积分10
1秒前
Echo完成签到,获得积分10
1秒前
RRRer完成签到,获得积分10
1秒前
秀丽凝安完成签到 ,获得积分10
2秒前
水煮电吹风的应助被Locker23采纳,获得10
2秒前
2秒前
wenxin完成签到,获得积分10
2秒前
lx完成签到 ,获得积分10
2秒前
Pepsi发布了新的文献求助30
2秒前
2秒前
2秒前
3秒前
handsomeliao完成签到,获得积分10
3秒前
丰富沛山完成签到 ,获得积分10
3秒前
澄澄橙橙紫完成签到,获得积分10
3秒前
4秒前
yuuu完成签到 ,获得积分10
4秒前
4秒前
永无完成签到,获得积分10
4秒前
cdercder的应助被L_采纳,获得10
4秒前
4秒前
马也发布了新的文献求助10
5秒前
5秒前
5秒前
Peiqi的应助被Maestro_S采纳,获得30
5秒前
6秒前
AXX041795发布了新的文献求助20
6秒前
6秒前
他说发布了新的文献求助10
6秒前
ll完成签到 ,获得积分10
7秒前
西瓜炒蛋完成签到,获得积分10
7秒前
8秒前
文文完成签到,获得积分10
8秒前
正在消融的冰完成签到,获得积分10
8秒前
wxs完成签到,获得积分10
9秒前
紧张的向雁完成签到,获得积分10
9秒前
闾丘翠桃发布了新的文献求助10
9秒前
鲤鱼晟睿完成签到,获得积分20
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105